Erdoğan E, Özdem B, Çimentepe ÖÖ, Tekedereli İ. Anatolian propolis extracts enhance cisplatin efficacy in ovarian cancer through AKT/mTOR pathway modulation and demonstrate antibacterial and antibiofilm activities. Med Oncol. 2025. https://doi.org/10.1007/s12032-025-02888-x.

Article  PubMed  Google Scholar 

Barnard ME, Meeks H, Jarboe EA, Albro J, Camp NJ, Doherty JA. Familial risk of epithelial ovarian cancer after accounting for gynaecological surgery: A population-based study. J Med Genet. 2022;60:119–27.

Article  PubMed  PubMed Central  Google Scholar 

Ha C, Hu L, Ren Y, Yang J, Xin L. SND1 confers chemoresistance to cisplatin-induced apoptosis by targeting GAS6-AKT in SKOV3 ovarian cancer cells. Med Oncol. 2022. https://doi.org/10.1007/s12032-022-01763-3.

Article  PubMed  Google Scholar 

Wang L, Wang X, Zhu X, Zhong L, Jiang Q, Wang Y, et al. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol Cancer. 2024. https://doi.org/10.1186/s12943-024-01967-3.

Article  PubMed  PubMed Central  Google Scholar 

Smolarz B, Biernacka K, Łukasiewicz H, Samulak D, Piekarska E, Romanowicz H, et al. Ovarian cancer—epidemiology, classification, pathogenesis, treatment, and estrogen receptors ’ molecular backgrounds. Int J Mol Sci. 2025;26:4611.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Siahestalkhi EK, Demiray A, Yaren A, Demiray AG, Tan S, Akça H. Characterization of lncRNAs contributing to drug resistance in epithelial ovarian cancer. Med Oncol. 2025. https://doi.org/10.1007/s12032-025-02628-1.

Article  PubMed  PubMed Central  Google Scholar 

Fanelli M, Formica M, Fusi V, Giorgi L, Micheloni M, Paoli P. New trends in platinum and palladium complexes as antineoplastic agents. Coord Chem Rev. 2016;310:41–79.

Article  CAS  Google Scholar 

Ai Z, Lu Y, Qiu S, Fan Z. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism. Cancer Lett. 2016;373:36–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li X, Guo Y, Qia Z, Zheng Y. WDR62 mediates MAPK/ERK pathway to stimulate DNA damage repair and attenuate cisplatin sensitivity in lung adenocarcinoma. Anticancer Drugs. 2025. https://doi.org/10.1097/cad.0000000000001682.

Article  PubMed  PubMed Central  Google Scholar 

Mirmohammadsadegh A, Mota R, Gustrau A, Hassan M, Nambiar S, Marini A, et al. ERK1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis. J Invest Dermatol. 2007;127:2207–15.

Article  CAS  PubMed  Google Scholar 

Choi J, Lee DH, Park SY, Seol JW. Diosmetin inhibits tumor development and block tumor angiogenesis in skin cancer. Biomed Pharmacother. 2019;117:109091.

Article  CAS  PubMed  Google Scholar 

Wang J, Ma S, Li L, Chen Y, Yang Q, Wang F, et al. Investigation into the in vivo mechanism of diosmetin in patients with breast cancer and COVID-19 using bioinformatics. Front Pharmacol. 2022;13:1–12.

Article  Google Scholar 

Koosha S, Mohamed Z, Sinniah A, Alshawsh MA. Evaluation of anti-tumorigenic effects of diosmetin against human colon cancer xenografts in athymic nude mice. Molecules. 2019;24:1–11.

Article  Google Scholar 

Kamran S, Sinniah A, Chik Z, Alshawsh MA. Diosmetin exerts synergistic effects in combination with 5-fluorouracil in colorectal cancer cells. Biomedicines. 2022;10:531.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koosha S, Mohamed Z, Sinniah A, Alshawsh MA. Investigation into the molecular mechanisms underlying the anti-proliferative and anti-tumorigenesis activities of Diosmetin against HCT-116 human colorectal cancer. Sci Rep. 2019;9:1–17.

Article  CAS  Google Scholar 

Zhao F, Hong X, Li D, Wei Z, Ci X, Zhang S. Diosmetin induces apoptosis in ovarian cancer cells by activating reactive oxygen species and inhibiting the Nrf2 pathway. Med Oncol. 2021;38:1–9.

Google Scholar 

Li J, Xu M, Wu N, Wu F, Chen J, Xu X, et al. Effects of citrus-derived diosmetin on melanoma: induction of apoptosis and autophagy mediated by PI3K/Akt/mTOR pathway inhibition. Anticancer Agents Med Chem. 2025. https://doi.org/10.2174/0118715206360266250115065234.

Article  PubMed  PubMed Central  Google Scholar 

Li W, Wan L, Zhai LY, Wang J. Effects of SC-560 in combination with cisplatin or taxol on angiogenesis in human ovarian cancer xenografts. Int J Mol Sci. 2014. https://doi.org/10.3390/ijms151019265.

Article  PubMed  PubMed Central  Google Scholar 

Chan ST, Lin YC, Chuang CH, Shiau RJ, Liao JW, Yeh SL. Oral and intraperitoneal administration of quercetin decreased lymphocyte DNA damage and plasma lipid peroxidation induced by TSA in vivo. BioMed Res Int. 2014. https://doi.org/10.1155/2014/580626.

Article  PubMed  PubMed Central  Google Scholar 

Desale SS, Soni KS, Romanova S, Cohen SM, Bronich TK. Targeted delivery of platinum-taxane combination therapy in ovarian cancer. J Control Release. 2015;220:651–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Madariaga A, Lheureux S, Oza AM. Tailoring ovarian cancer treatment: Implications of BRCA1/2 mutations. Cancers (Basel). 2019;11:1–32.

Article  Google Scholar 

Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Prim. 2016;2:1–22.

Google Scholar 

Miow QH, Tan TZ, Ye J, Lau JA, Yokomizo T, Thiery JP, et al. Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene. 2014;34:1899–907.

Article  PubMed  Google Scholar 

Ju X, Yu H, Liang D, Jiang T, Liu Y, Chen L, et al. LDR reverses DDP resistance in ovarian cancer cells by affecting ERCC-1, Bcl-2, Survivin and Caspase-3 expressions. Biomed Pharmacother. 2018;102:549–54.

Article  CAS  PubMed  Google Scholar 

Zhou F, Yang X, Zhao H, Liu Y, Feng Y, An R, et al. Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer. Theranostics. 2018;8:5200–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feliu J, Heredia-Soto V, Gironés R, Jiménez-Munarriz B, Saldaña J, Guillén-Ponce C, et al. Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients. Clin Transl Oncol. 2020;22:457–67.

Article  CAS  PubMed  Google Scholar 

Mohell N, Alfredsson J, Fransson A, Uustalu M, Byström S, Gullbo J, et al. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. Cell Death Dis. 2015;6:1–11.

Article  Google Scholar 

Ning R, Chen G, Fang R, Zhang Y, Zhao W, Qian F. Diosmetin inhibits cell proliferation and promotes apoptosis through STAT3/c-Myc signaling pathway in human osteosarcoma cells. Biol Res. 2021;54:1–15.

Article  Google Scholar 

Liu Y, Shao Z, Liao Y, Xia X, Huang C, He J, et al. Targeting SKP2/Bcr-Abl pathway with Diosmetin suppresses chronic myeloid leukemia proliferation. Eur J Pharmacol. 2020;883:173366.

Article  CAS  PubMed  Google Scholar 

Liu F, Yang X, Geng M, Huang M. Targeting ERK, an Achilles’ Heel of the MAPK pathway, in cancer therapy. Acta Pharm Sin B. 2018;8:552–62.

Article  PubMed  PubMed Central  Google Scholar 

Burotto M, Chiou VL, Lee JM, Kohn EC. The MAPK pathway across different malignancies: A new perspective. Cancer. 2014;120:3446–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weir NM, Selvendiran K, Kutala VK, Tong L, Vishwanath S, Rajaram M, et al. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther. 2007. https://doi.org/10.4161/cbt.6.2.3577.

Article  PubMed  PubMed Central